(0.20%) 5 471.54 points
(0.18%) 39 188 points
(0.67%) 17 852 points
(1.73%) $82.95
(-4.08%) $2.50
(-0.05%) $2 338.50
(0.25%) $29.64
(-1.32%) $988.70
(-0.13%) $0.932
(-0.10%) $10.66
(0.01%) $0.791
(1.03%) $86.61
Live Chart Being Loaded With Signals
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology...
Stats | |
---|---|
今日成交量 | 35 997 |
平均成交量 | 95 254 |
市值 | 39.92M |
EPS | $-0.120 ( Q1 | 2024-05-09 ) |
下一个收益日期 | ( $0 ) 2024-07-30 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-1.250 (Sector) 42.63 (Industry) 0 |
ATR14 | $0.0160 (2.18%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-02 | Jones Edward Raymond | Buy | 22 000 | Stock Option (Right to Buy) |
2024-04-02 | Deliargyris Efthymios | Buy | 61 000 | Common Stock |
2024-04-02 | Deliargyris Efthymios | Buy | 86 000 | Stock Option (Right to Buy) |
2024-04-02 | Sobel Alan D. | Buy | 22 000 | Stock Option (Right to Buy) |
2024-04-02 | Bloch Kathleen P. | Buy | 65 000 | Common Stock |
INSIDER POWER |
---|
76.99 |
Last 100 transactions |
Buy: 4 191 625 | Sell: 429 500 |
音量 相关性
Cytosorbents Corp 相关性 - 货币/商品
Cytosorbents Corp 财务报表
Annual | 2023 |
营收: | $36.35M |
毛利润: | $22.39M (61.60 %) |
EPS: | $-0.640 |
FY | 2023 |
营收: | $36.35M |
毛利润: | $22.39M (61.60 %) |
EPS: | $-0.640 |
FY | 2022 |
营收: | $29.36M |
毛利润: | $15.40M (52.47 %) |
EPS: | $-0.750 |
FY | 2021 |
营收: | $43.17M |
毛利润: | $32.12M (74.41 %) |
EPS: | $-0.570 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Cytosorbents Corp
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。